Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 8/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL790348 | 0.87 | BTN3A1 (0.50) | BTN3A1ELANEL3MBTL1KMT2AMAPK1 | |
| SCHEMBL784174 | 0.86 | BTN3A1 (0.43) | BTN3A1ELANEL3MBTL1ALDH1A1 | |
| SCHEMBL19644693 | 0.86 | BTN3A1 (0.54) | BTN3A1TDP1LMNASMN1; SMN2MMP8 | |
| SCHEMBL21158533 | 0.86 | BTN3A1 (0.57) | BTN3A1TDP1LMNASMN1; SMN2MMP8 | |
| SCHEMBL807682 | 0.86 | BTN3A1 (0.57) | BTN3A1TDP1LMNASMN1; SMN2MMP8 | |
| SCHEMBL23992573 | 0.86 | BTN3A1 (0.57) | BTN3A1TDP1LMNASMN1; SMN2MMP8 | |
| SCHEMBL18067181 | 0.86 | BTN3A1 (0.54) | BTN3A1TDP1LMNASMN1; SMN2MMP8 | |
| SCHEMBL14466574 | 0.86 | BTN3A1 (0.57) | BTN3A1TDP1LMNASMN1; SMN2MMP8 | |
| SCHEMBL19765980 | 0.85 | BTN3A1 (0.53) | BTN3A1TDP1LMNASMN1; SMN2MMP8 | |
| SCHEMBL18061741 | 0.85 | BTN3A1 (0.53) | BTN3A1TDP1LMNASMN1; SMN2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190085010-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2019-03-21 | — | — | US | disclosed |
| US-20180105549-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2018-04-19 | — | — | US | disclosed |
| US-20180105549-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2018-04-19 | — | — | US | disclosed |
| EP-3252066-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2017-12-06 | — | — | EP | disclosed |
| US-9828408-B2 | HCV polymerase inhibitors | MEDIVIR AB (SE) | 2017-11-28 | — | — | US | disclosed |
| US-9828408-B2 | HCV polymerase inhibitors | MEDIVIR AB (SE) | 2017-11-28 | — | — | US | disclosed |
| EP-3041855-B1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2017-07-26 | — | — | EP | disclosed |
| US-20170107244-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2017-04-20 | — | — | US | disclosed |
| US-20170107244-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2017-04-20 | — | — | US | disclosed |
| US-9540411-B2 | HCV polymerase inhibitors | MEDIVIR AB (SE) | 2017-01-10 | — | — | US | disclosed |
| US-20160340380-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-11-24 | — | — | US | disclosed |
| US-20160340380-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-11-24 | — | — | US | disclosed |
| US-9481703-B2 | HCV polymerase inhibitors | MEDIVIR AB (SE) | 2016-11-01 | — | — | US | disclosed |
| US-9481703-B2 | HCV polymerase inhibitors | MEDIVIR AB (SE) | 2016-11-01 | — | — | US | disclosed |
| US-20160271160-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-09-22 | — | — | US | disclosed |
| US-20160271160-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-09-22 | — | — | US | disclosed |
| US-20150175648-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-06-25 | — | — | US | disclosed |
| US-20150175648-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-06-25 | — | — | US | disclosed |
| WO-2015056213-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015034420-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160271160-A1 | HCV POLYMERASE INHIBITORS | POLI, POLB, POLL | BTN3A1 2995/4885TDP1 1595/4885LMNA 2858/4885 |
| US-20170107244-A1 | HCV POLYMERASE INHIBITORS | POLI, POLB, POLL | BTN3A1 2995/4885TDP1 1595/4885LMNA 2858/4885 |
| US-20190085010-A1 | HCV POLYMERASE INHIBITORS | POLI, POLB, POLL | BTN3A1 2995/4885TDP1 1595/4885LMNA 2858/4885 |
| US-20180105549-A1 | HCV POLYMERASE INHIBITORS | POLI, POLB, POLL | BTN3A1 2995/4885TDP1 1595/4885LMNA 2858/4885 |
| US-20150175648-A1 | HCV POLYMERASE INHIBITORS | POLI, POLB, POLL | BTN3A1 2995/4885TDP1 1595/4885LMNA 2858/4885 |
| US-20160340380-A1 | HCV POLYMERASE INHIBITORS | POLI, POLB, POLL | BTN3A1 2995/4885TDP1 1595/4885LMNA 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.